| Literature DB >> 31620000 |
Christina M A P Schuh1, Bruna Benso2,3, Sebastian Aguayo2.
Abstract
The diagnosis and management of pain is an everyday occurrence in dentistry, and its effective control is essential to ensure the wellbeing of patients. Most tooth-associated pain originates from the dental pulp, a highly vascularized and innervated tissue, which is encased within mineralized dentin. It plays a crucial role in the sensing of stimuli from the local environment, such as infections (i.e. dental caries) and traumatic injury, leading to a local inflammatory response and subsequently to an increase in intra-pulp pressure, activating nerve endings. However, thermal, chemical, and mechanical stimuli also have the ability to generate dental pulp pain, which presents mechanisms highly specific to this tissue and which have to be considered in pain management. Traditionally, the management of dental pulp pain has mostly been pharmacological, using non-steroidal anti-inflammatory drugs (NSAIDs) and opioids, or restorative (i.e. removal of dental caries), or a combination of both. Both research areas continuously present novel and creative approaches. This includes the modulation of thermo-sensitive transient receptor potential cation channels (TRP) by newly designed drugs in pharmacological research, as well as the use of novel biomaterials, stem cells, exosomes and physical stimulation to obtain pulp regeneration in regenerative medicine. Therefore, the aim of this review is to present an up-to-date account of causes underlying dental pain, novel treatments involving the control of pain and inflammation and the induction of pulp regeneration, as well as insights in pain in dentistry from the physiological, pharmacological, regenerative and clinical perspectives.Entities:
Keywords: collagen; dental caries; dentin; dentistry; endodontics; pain; pharmacology; regenerative medicine
Year: 2019 PMID: 31620000 PMCID: PMC6759635 DOI: 10.3389/fphar.2019.01068
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
Figure 1Tooth and dental pulp anatomy. (A) Diagrammatic representation of a tooth cross-section illustrating the organization of enamel, dentin, cement and dental pulp within the tooth structure. The dental pulp is vascularized and innervated through the root apex, which provides nociception via afferent trigeminal nerves. (B) The odontoblast layer is located in the interphase between dentin and dental pulp, with prolongations extending into dentin via dentinal tubules. Sensory nerve fibers penetrate the odontoblast layer and enter the initial portion of dentinal tubules, thus permeability or alterations in dentin can trigger nociception.
Pharmacological treatment possibilities to control post-operative pain in dentistry with opioids alone and in different combinations.
| Authors* | Study design | Sample size | Pharmacological treatment groups | Outcome instrument | Postoperative measurement | Postoperative assessment of pain | Study conclusions | ||
|---|---|---|---|---|---|---|---|---|---|
|
|
| ( | Randomized clinical trial, | 100 | Placebo | 10-point VAS | Placebo 3.2 (2.6–3.9) | 24 h | A single oral dose of Naproxen, Novafen and Tramadol taken immediately after dental treatment reduced postoperative pain following pulpectomy. |
|
| ( | Randomized clinical trial, | 120 | Placebo | 4-point rate scale | Placebo 1.27 (0.25) | 6 h | Propiram fumarate 50 mg is an effective oral analgesic similar to codeine sulfate 60 mg, with the possibility of a longer effect. | |
|
|
| ( | Systematic- review with meta-analysis | 1376 | Acetaminophen 650 mg | NNT (95% CI) PGE** | 4.5 (3.6–6.1) | 8 h | Overall, this meta-analysis demonstrated analgesic superiority of the combination drug over its components, without additional toxicity. |
|
| ( | Randomized clinical trial, | 393 | Placebo (1:6:6, respectively) | TOPAR6*** | Placebo 3.4 (1.0–5.8) | 6 h | In this study of moderate to severe postoperative dental pain, the analgesic efficacy of Rofecoxib 50 mg was greater than that of codeine/acetaminophen, with a lower incidence of adverse events and nausea. | |
|
| ( | Randomized clinical trial, | 212 | Placebo (1:3:3, respectively) | GLOBAL24# | Placebo 0.3 (0.2) | 24 h | The superior efficacy of Rofecoxib 50 mg compared to oxycodone/acetaminophen |
*All studies included in this summarized tables were checked for GRADE criteria; **PGE- Patient Global Evidence; ***TOPAR6- pain relief over 6 h; #GLOBAL24 - Global assessment of treatment at 24 h.
Figure 2Overview of current and potential regenerative medicine approaches for dental pain treatment.